AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript

Karen Zaderej: Yeah, we — think of it as from a sales rep number that we will stay very close to that 116 number maybe up or down a few reps from that, but it will stay very close to the 116 number. In terms of new things, again, we’ve already talked about the Avive+, which will be coming up here shortly. So we’ll have a new product, continuing to focus in different parts of nerve protection. We aren’t looking at anything here in the short term of a big launch in a new application, but we are doing continued development work in several application areas and see that the opportunity for nerve repair is pretty expansive because nerves run all over the body and are injured in many types of procedures. And so we have a medical affairs team that really focuses on Avance techniques in nerve repair and looking at new expansion areas.

So at this point, I don’t have anything that I want to tell you is a confirmed expansion area, but to say that our R&D team continues to work on it and sees some promising new areas for us to look into.

Ross Osborn: Great. Thank you.

Operator: Thank you. We’ve reached the end of our question-and-answer session. I’d like to turn the floor back over to Karen for any further or closing comments.

Karen Zaderej: Well, thank you. As we conclude today’s earnings call, I want to express my appreciation to our team for their exceptional efforts, and all the participants for your attention and contributions. The dedication of our staff has been pivotal in achieving the milestones we discussed today, and we look forward to sharing our continued progress with you in the future.

Operator: Thank you. That does conclude today’s teleconference webcast. You may disconnect your line at this time, and have a wonderful day. We thank you for your participation today.